Papakonstantinou Ilias, Tsioufis Konstantinos, Katsi Vasiliki
4th Department of Internal Medicine, Evangelismos General Hospital, 10676 Athens, Greece.
1st Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece.
Curr Issues Mol Biol. 2024 Dec 23;46(12):14514-14541. doi: 10.3390/cimb46120872.
Initially intended to control blood glucose levels in patients with type 2 diabetes, semaglutide, a potent glucagon-like peptide 1 analogue, has been established as an effective weight loss treatment by controlling appetite. Integrating the latest clinical trials, semaglutide in patients with or without diabetes presents significant therapeutic efficacy in ameliorating cardiometabolic risk factors and physical functioning, independent of body weight reduction. Semaglutide may modulate adipose tissue browning, which enhances human metabolism and exhibits possible benefits in skeletal muscle degeneration, accelerated by obesity and ageing. This may be attributed to anti-inflammatory, mitochondrial biogenesis, antioxidant and autophagy-regulating effects. However, most of the supporting evidence on the mechanistic actions of semaglutide is preclinical, demonstrated in rodents and not actually confirmed in humans, therefore warranting caution in the interpretation. This article aims to explore potential innovative molecular mechanisms of semaglutide action in restoring the balance of several interlinking aspects of metabolism, pointing to distinct functions in inflammation and oxidative stress in insulin-sensitive musculoskeletal and adipose tissues. Moreover, possible applications in protection from infections and anti-aging properties are discussed. Semaglutide enhancement of the core molecular mechanisms involved in the progress of obesity and diabetes, although mostly preclinical, may provide a framework for future research applications in human diseases overall.
司美格鲁肽是一种强效胰高血糖素样肽1类似物,最初旨在控制2型糖尿病患者的血糖水平,现已被确认为一种通过控制食欲来有效减肥的治疗方法。综合最新的临床试验,司美格鲁肽在糖尿病患者和非糖尿病患者中,无论体重是否减轻,在改善心脏代谢危险因素和身体功能方面均具有显著的治疗效果。司美格鲁肽可能会调节脂肪组织褐变,这会增强人体新陈代谢,并对因肥胖和衰老而加速的骨骼肌退化表现出潜在益处。这可能归因于抗炎、线粒体生物合成、抗氧化和自噬调节作用。然而,关于司美格鲁肽作用机制的大多数支持证据都是临床前的,在啮齿动物中得到证实,但尚未在人体中实际得到确认,因此在解释时需要谨慎。本文旨在探索司美格鲁肽作用的潜在创新分子机制,以恢复代谢几个相互关联方面的平衡,指出其在胰岛素敏感的肌肉骨骼和脂肪组织的炎症和氧化应激中的独特功能。此外,还讨论了其在预防感染和抗衰老特性方面的可能应用。司美格鲁肽增强肥胖和糖尿病进展中涉及的核心分子机制,尽管大多是临床前的,但可能为未来人类疾病的研究应用提供一个框架。